In 23% to 50% of intrahepatic cholangiocarcinoma and 30% to 40% of extrahepatic cholangiocarcinoma, the KRAS gene often has mutations, which accelerate tumor progression (73, 74). The gene discussed is KRAS; the disease is intrahepatic cholangiocarcinoma.